Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schools, Medical | 3 | 2021 | 208 | 0.960 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2006 | 42 | 0.900 |
Why?
|
| Cultural Diversity | 1 | 2021 | 187 | 0.600 |
Why?
|
| Students, Medical | 1 | 2021 | 153 | 0.580 |
Why?
|
| Milk, Human | 1 | 2018 | 51 | 0.560 |
Why?
|
| Health Status Disparities | 3 | 2018 | 702 | 0.520 |
Why?
|
| Breast Feeding | 1 | 2018 | 123 | 0.520 |
Why?
|
| Postmenopause | 2 | 2005 | 139 | 0.420 |
Why?
|
| Estrogens | 2 | 2013 | 202 | 0.410 |
Why?
|
| Menopause | 4 | 2007 | 63 | 0.370 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.350 |
Why?
|
| Kidney Diseases | 1 | 2013 | 170 | 0.340 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.330 |
Why?
|
| Cardiovascular Diseases | 3 | 2013 | 728 | 0.300 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2006 | 12 | 0.290 |
Why?
|
| Estradiol | 3 | 2007 | 269 | 0.250 |
Why?
|
| Contraceptive Agents, Female | 1 | 2006 | 25 | 0.240 |
Why?
|
| Bone Density | 1 | 2006 | 102 | 0.230 |
Why?
|
| Medroxyprogesterone | 2 | 2002 | 2 | 0.230 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2002 | 11 | 0.230 |
Why?
|
| Ethinyl Estradiol | 2 | 2002 | 11 | 0.230 |
Why?
|
| Complementary Therapies | 1 | 2005 | 51 | 0.230 |
Why?
|
| Hot Flashes | 4 | 2005 | 8 | 0.220 |
Why?
|
| Humans | 22 | 2021 | 42113 | 0.210 |
Why?
|
| Women's Health | 1 | 2005 | 158 | 0.210 |
Why?
|
| Exercise Therapy | 1 | 2004 | 83 | 0.210 |
Why?
|
| Female | 19 | 2021 | 23980 | 0.190 |
Why?
|
| Momordica | 1 | 2022 | 14 | 0.190 |
Why?
|
| United States | 5 | 2021 | 5068 | 0.190 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 196 | 0.170 |
Why?
|
| Health Services Accessibility | 2 | 2011 | 680 | 0.170 |
Why?
|
| Endometriosis | 1 | 2002 | 81 | 0.160 |
Why?
|
| History, 20th Century | 1 | 2021 | 124 | 0.160 |
Why?
|
| Oocyte Donation | 1 | 2010 | 1 | 0.160 |
Why?
|
| Educational Measurement | 1 | 2021 | 100 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 57 | 0.160 |
Why?
|
| Catechin | 2 | 2010 | 38 | 0.150 |
Why?
|
| Antisickling Agents | 1 | 2009 | 14 | 0.150 |
Why?
|
| Hypogonadism | 1 | 2009 | 23 | 0.150 |
Why?
|
| Educational Status | 1 | 2021 | 335 | 0.150 |
Why?
|
| Minority Groups | 3 | 2021 | 663 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 2009 | 34 | 0.150 |
Why?
|
| Milk Banks | 1 | 2018 | 3 | 0.150 |
Why?
|
| Infertility, Male | 1 | 2009 | 46 | 0.150 |
Why?
|
| Uterine Neoplasms | 2 | 2010 | 51 | 0.150 |
Why?
|
| Leiomyoma | 2 | 2010 | 40 | 0.140 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 406 | 0.140 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 39 | 0.140 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2018 | 35 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2019 | 158 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 570 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 175 | 0.130 |
Why?
|
| Chemotactic Factors | 1 | 2007 | 8 | 0.130 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 18 | 0.130 |
Why?
|
| HIV-1 | 1 | 2022 | 747 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2009 | 185 | 0.130 |
Why?
|
| Medicare | 1 | 2019 | 325 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 233 | 0.130 |
Why?
|
| Chemokines | 1 | 2007 | 97 | 0.120 |
Why?
|
| Carcinoma | 1 | 2007 | 106 | 0.120 |
Why?
|
| Infant | 1 | 2018 | 1142 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2010 | 1420 | 0.110 |
Why?
|
| Healthy People Programs | 1 | 2005 | 25 | 0.110 |
Why?
|
| Public Health Administration | 1 | 2005 | 26 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 55 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2005 | 178 | 0.100 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2002 | 21 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2002 | 102 | 0.090 |
Why?
|
| Accreditation | 1 | 2012 | 19 | 0.090 |
Why?
|
| Georgia | 1 | 2012 | 189 | 0.090 |
Why?
|
| Middle Aged | 6 | 2007 | 11790 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2012 | 141 | 0.080 |
Why?
|
| Animals | 7 | 2018 | 16694 | 0.080 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 74 | 0.070 |
Why?
|
| HIV Infections | 1 | 2022 | 2535 | 0.070 |
Why?
|
| Vulnerable Populations | 1 | 2009 | 163 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2007 | 8 | 0.070 |
Why?
|
| Cystitis | 1 | 2007 | 7 | 0.070 |
Why?
|
| Health Personnel | 1 | 2009 | 262 | 0.060 |
Why?
|
| Male | 4 | 2021 | 22745 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2012 | 467 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 42 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2007 | 43 | 0.060 |
Why?
|
| Osteocalcin | 1 | 2006 | 5 | 0.060 |
Why?
|
| Histone Deacetylases | 1 | 2007 | 61 | 0.060 |
Why?
|
| Antioxidants | 1 | 2010 | 439 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2007 | 154 | 0.060 |
Why?
|
| Female Urogenital Diseases | 1 | 2005 | 3 | 0.060 |
Why?
|
| Pituitary-Adrenal System | 1 | 2005 | 41 | 0.060 |
Why?
|
| Social Justice | 2 | 2011 | 64 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 49 | 0.060 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2005 | 55 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2006 | 115 | 0.060 |
Why?
|
| Urogenital System | 1 | 2005 | 2 | 0.060 |
Why?
|
| Vasomotor System | 1 | 2005 | 3 | 0.060 |
Why?
|
| Apoptosis | 2 | 2010 | 1541 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2005 | 50 | 0.060 |
Why?
|
| Atrophy | 1 | 2005 | 51 | 0.060 |
Why?
|
| Ovarian Follicle | 1 | 2005 | 40 | 0.060 |
Why?
|
| Mice | 5 | 2010 | 6490 | 0.050 |
Why?
|
| Reproduction | 1 | 2005 | 92 | 0.050 |
Why?
|
| Lipids | 1 | 2006 | 256 | 0.050 |
Why?
|
| Plant Extracts | 2 | 2022 | 303 | 0.050 |
Why?
|
| Body Weight | 1 | 2006 | 428 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2004 | 77 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 1221 | 0.050 |
Why?
|
| Aged | 4 | 2007 | 7958 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2010 | 506 | 0.050 |
Why?
|
| Estradiol Congeners | 1 | 2002 | 2 | 0.050 |
Why?
|
| Progesterone Congeners | 1 | 2002 | 2 | 0.050 |
Why?
|
| Uterine Hemorrhage | 1 | 2002 | 14 | 0.050 |
Why?
|
| Danazol | 1 | 2002 | 3 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2002 | 8 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2002 | 39 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2002 | 48 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2006 | 1570 | 0.050 |
Why?
|
| Endometrium | 1 | 2002 | 60 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2006 | 1728 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 149 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 189 | 0.040 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 2010 | 1 | 0.040 |
Why?
|
| Embryo Research | 1 | 2010 | 2 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 357 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2010 | 8 | 0.040 |
Why?
|
| Quality of Life | 1 | 2005 | 598 | 0.040 |
Why?
|
| Health Services Research | 1 | 2011 | 161 | 0.040 |
Why?
|
| Adult | 3 | 2007 | 13437 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2010 | 49 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2010 | 47 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 43 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 137 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 224 | 0.040 |
Why?
|
| Depression | 1 | 2005 | 837 | 0.040 |
Why?
|
| Research Design | 1 | 2010 | 370 | 0.030 |
Why?
|
| Testis | 1 | 2009 | 203 | 0.030 |
Why?
|
| Physicians | 1 | 2019 | 180 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2007 | 39 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 658 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 310 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 235 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 531 | 0.030 |
Why?
|
| Boston | 1 | 2005 | 31 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 379 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 309 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2005 | 38 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2009 | 2111 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2007 | 355 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 146 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1554 | 0.020 |
Why?
|
| Decision Making | 1 | 2005 | 242 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 350 | 0.020 |
Why?
|
| Camellia sinensis | 1 | 2009 | 3 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 76 | 0.020 |
Why?
|
| Models, Educational | 1 | 2009 | 46 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 3933 | 0.020 |
Why?
|
| Tea | 1 | 2009 | 46 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2009 | 36 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 152 | 0.020 |
Why?
|
| Prejudice | 1 | 2009 | 116 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 403 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2009 | 230 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2007 | 32 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 15 | 0.020 |
Why?
|
| Fimbriae Proteins | 1 | 2007 | 21 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2007 | 80 | 0.020 |
Why?
|
| Butyrates | 1 | 2007 | 34 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 34 | 0.020 |
Why?
|
| Acetylation | 1 | 2007 | 108 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 44 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 52 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2007 | 128 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1111 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 101 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 167 | 0.020 |
Why?
|
| Anovulation | 1 | 2005 | 4 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 2005 | 17 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2005 | 47 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 62 | 0.010 |
Why?
|
| Estrous Cycle | 1 | 2005 | 37 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 44 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 1845 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 457 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2007 | 884 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 436 | 0.010 |
Why?
|
| Disease Progression | 1 | 2007 | 660 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 599 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2007 | 461 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 1679 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 649 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 1010 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1265 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 1804 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 1733 | 0.010 |
Why?
|
Montgomery Rice's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(194)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(14)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_